LINKS TO RELEVANT PUBLICATIONS

Comparative in-vitro activities of MCB3681 and 8 comparators against 200 Clostridium difficile isolates with known ribotypes and diverse geographical spread.
Freeman J, Pilling S, Vernon J, Wilcox MH
Poster #EV0627, ECCMID2016, 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, The Netherlands, April 9–12, 2016
http://eccmidlive.org/#resources/comparative-in-vitro-activities-of-mcb3681-and-8-comparators-against-200-clostridium-difficile-isolates-with-known-ribotypes-and-diverse-geographical-spread-9cb9dcea-3c2f-4c98-a322-7c10dd91bca3

Analysis of effects of MCB3681, the antibacterially active substance of prodrug MCB3837, on human resident microflora as proof of principle.
Dalhoff A, Rashid MU, Kapsner T, Panagiotidis G, Weintraub A, Nord CE.
Clin Microbiol Infect. 2015 Aug;21(8):767.e1-4. doi: 10.1016/j.cmi.2015.05.025. Epub 2015 Jun 3.
http://www.ncbi.nlm.nih.gov/pubmed/26047854

In vitro activity of MCB3681 against Clostridium difficile strains.
Rashid MU, Dalhoff A, Weintraub A, Nord CE.
Anaerobe. 2014 Aug;28:216-9. doi: 10.1016/j.anaerobe.2014.07.001. Epub 2014 Jul 10.
http://www.ncbi.nlm.nih.gov/pubmed/25016084

Ecological impact of MCB3837 on the normal human microbiota.
Rashid MU, Dalhoff A, Bäckström T, Björkhem-Bergman L, Panagiotidis G, Weintraub A, Nord CE.
Int J Antimicrob Agents. 2014 Aug;44(2):125-30. doi: 10.1016/j.ijantimicag.2014.03.016. Epub 2014 May 23.
http://www.ncbi.nlm.nih.gov/pubmed/24931053

Alternative strategies for proof-of-principle studies of antibacterial agents.
Dalhoff A, Weintraub A, Nord CE.
Antimicrob Agents Chemother. 2014 Aug;58(8):4257-63. doi: 10.1128/AAC.02473-14. Epub 2014 May 27.
http://www.ncbi.nlm.nih.gov/pubmed/24867989

Back